Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Health
  • Nyse
  • Yacht Buyer
  • Banking
  • Stocks
  • Finance
ncarol.com

Lineus Medical Announces a Reduction in Price for SafeBreak Vascular
ncarol.com/10271492

Trending...
  • VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
SafeBreak Vascular Lineus Medical
FAYETTEVILLE, Ark. - ncarol.com -- Lineus Medical announces a significant reduction in price of nearly 15% for its flagship product, SafeBreak Vascular, in the United States. After creating a new device classification with the FDA and becoming the first break-away device available for IV lines in the US, SafeBreak Vascular was first released with a list price of $6.90. Since its release, increased sales volume and concentrated efforts toward manufacturing efficiencies support a price adjustment with a new list price of $5.90, effective on September 1st, 2024.

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications1.  When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

More on ncarol.com
  • Simpalm Staffing Services Launched its Refreshed Website for Remote Staffing Services
  • Claude Riveloux Review 2026: How the $10B Fund Manager Dispels 'Scam' Rumors Through Education
  • Pure Energy Electrical Services, LLC Announces Strong Start to 2026, Reinforcing Customer-First Electrical Service Across Northeast Florida
  • Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida
  • Sellvia Market Expands Curated Store Portfolio for Dropshipping Sellers

"A large focus of our strategy is maximizing our economic value proposition for the hospital." Lineus Medical's Vice President of Sales, Larry Hayes comments, "Reducing our price allows for both current and new accounts to take advantage of cost savings, and in doing so, we are making it easier for hospitals to invest in improved vascular access care for their patients."

Vance Clement, CEO of Lineus Medical, stated, "Inflation is hitting everyone, and we are all used to prices going up.  This is especially true in healthcare, where prices never go down. However, SafeBreak, which is proudly made in the USA, is changing that. As we continue to grow, we will keep investing in manufacturing so that we can lower the cost of SafeBreak again in the future."

Lineus Medical is committed to improving patient safety and advancing vascular access care and believes that this price reduction is another important step in our mission to remove the pains associated with medical lines.  Anyone interested in SafeBreak Vascular's price reduction can visit our website www.lineusmed.com to learn more.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
  • Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
  • ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
  • Memelinked Social Media powered by cryptocurrency launching July 2026
  • DwellSafe and Bruno Partner to Bring Clinician-Backed Stairlift Education to Families
  • Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
  • Leoforce Releases Beyond Programmatic: A Practical Guide to Long-Term Hiring Outcomes
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
  • Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
  • Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
  • Distributed Social Media - Own Your Content
  • Tarrytown Expocare Pharmacy Announces Strategic Leadership Appointments to Accelerate Growth and Innovation
  • New Environmental Thriller "The Star Thrower" Reimagines a Classic Lesson in Individual Impact
  • Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
  • Interview: Why I Sponsored Carson Ware - The Full Story
  • March Is Skiing's Smartest Buying Window
_catLbl0 _catLbl1

Popular on ncarol.com

  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies - 118
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments - 102
  • Still Using Ice? FrostSkin Reinvents Hydration - 102
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Cold. Clean. Anywhere. Meet FrostSkin
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)

Similar on ncarol.com

  • Yoga Retreats, Ecstatic Dance & Spiritual App launched
  • Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
  • ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
  • DwellSafe and Bruno Partner to Bring Clinician-Backed Stairlift Education to Families
  • Leoforce Releases Beyond Programmatic: A Practical Guide to Long-Term Hiring Outcomes
  • Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
  • Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
  • National Expansion Ignited Across Amazon $AMZN, Chewy $CHWY & Walmart $WMT: NDT Pharmaceuticals, Inc. (Stock Symbol: NDTP) $NDTP
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute